NCBI Taxonomy: 373097

Gambierdiscus (ncbi_taxid: 373097)

found 8 associated metabolites at genus taxonomy rank level.

Child Taxonomies: Gambierdiscus honu, Gambierdiscus silvae, Gambierdiscus lewisii, Gambierdiscus toxicus, Gambierdiscus holmesii, Gambierdiscus lapillus, Gambierdiscus balechii, Gambierdiscus pacificus, Gambierdiscus australes, Gambierdiscus jejuensis, Gambierdiscus scabrosus, Gambierdiscus caribaeus, Gambierdiscus cheloniae, Gambierdiscus belizeanus, Gambierdiscus carpenteri, Gambierdiscus excentricus, Gambierdiscus vietnamensis, unclassified Gambierdiscus, Gambierdiscus carolinianus, Gambierdiscus polynesiensis, Gambierdiscus cf. yasumotoi IR4G, Gambierdiscus cf. yasumotoi CAWD 210, Gambierdiscus cf. yasumotoi Suda-2013

Methotrexate

(2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid

C20H22N8O5 (454.1713082)

Methotrexate is only found in individuals that have used or taken this drug. It is an antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of tetrahydrofolate dehydrogenase and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. [PubChem]Methotrexate anti-tumor activity is a result of the inhibition of folic acid reductase, leading to inhibition of DNA synthesis and inhibition of cellular replication. The mechanism involved in its activity against rheumatoid arthritis is not known. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BA - Folic acid analogues L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents C471 - Enzyme Inhibitor > C2153 - Dihydrofolate Reductase Inhibitor D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists CONFIDENCE standard compound; INTERNAL_ID 2730 D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents D018501 - Antirheumatic Agents D003879 - Dermatologic Agents Corona-virus KEIO_ID M048 Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

Gambierol

(1S,3R,5S,7R,10S,13S,15R,17S,20R,22S,24R,26S,27S,29S,31R,33S,35R)-11-[(1Z,3Z)-hepta-1,3,6-trienyl]-29-(3-hydroxypropyl)-3,5,10,24,26-pentamethyl-2,6,12,16,21,25,30,34-octaoxaoctacyclo[18.16.0.03,17.05,15.07,13.022,35.024,33.026,31]hexatriacont-8-ene-10,27-diol

C43H64O11 (756.4448394)

Methotrexate

L(+)-Amethopterin hydrate

C20H22N8O5 (454.1713082)

L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BA - Folic acid analogues L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents C471 - Enzyme Inhibitor > C2153 - Dihydrofolate Reductase Inhibitor D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents D018501 - Antirheumatic Agents D003879 - Dermatologic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

(3s)-3-[(2s,3r,5s)-5-[(2r)-3-[(1s,3r,5s,7r,9s,11r,14r,16r,17s,18s,20s,21s,22z,25r,27s,29r,31s,34r,35s,37r,39s,41r)-17,34-dihydroxy-11-[(2e,4r)-5-hydroxy-2,4-dimethylpent-2-en-1-yl]-9,18,21,27,29,34-hexamethyl-12-methylidene-2,6,10,15,19,26,30,36,40-nonaoxanonacyclo[23.18.0.0³,²⁰.0⁵,¹⁸.0⁷,¹⁶.0⁹,¹⁴.0²⁷,⁴¹.0²⁹,³⁹.0³¹,³⁷]tritetracont-22-en-35-yl]-2-hydroxypropyl]-3-methyloxolan-2-yl]butanoic acid

(3s)-3-[(2s,3r,5s)-5-[(2r)-3-[(1s,3r,5s,7r,9s,11r,14r,16r,17s,18s,20s,21s,22z,25r,27s,29r,31s,34r,35s,37r,39s,41r)-17,34-dihydroxy-11-[(2e,4r)-5-hydroxy-2,4-dimethylpent-2-en-1-yl]-9,18,21,27,29,34-hexamethyl-12-methylidene-2,6,10,15,19,26,30,36,40-nonaoxanonacyclo[23.18.0.0³,²⁰.0⁵,¹⁸.0⁷,¹⁶.0⁹,¹⁴.0²⁷,⁴¹.0²⁹,³⁹.0³¹,³⁷]tritetracont-22-en-35-yl]-2-hydroxypropyl]-3-methyloxolan-2-yl]butanoic acid

C60H94O16 (1070.6541524)

(3s)-3-[(2r,3s,5r)-5-[(2r)-3-[(1s,3r,5s,7r,9s,11r,14r,16s,17s,18r,20s,21s,22z,25r,27s,29r,31s,34s,35s,37r,39s,41r)-17,34-dihydroxy-11-[(2e,4r)-5-hydroxy-2,4-dimethylpent-2-en-1-yl]-9,18,21,27,29,34-hexamethyl-12-methylidene-2,6,10,15,19,26,30,36,40-nonaoxanonacyclo[23.18.0.0³,²⁰.0⁵,¹⁸.0⁷,¹⁶.0⁹,¹⁴.0²⁷,⁴¹.0²⁹,³⁹.0³¹,³⁷]tritetracont-22-en-35-yl]-2-hydroxypropyl]-3-methyloxolan-2-yl]butanoic acid

(3s)-3-[(2r,3s,5r)-5-[(2r)-3-[(1s,3r,5s,7r,9s,11r,14r,16s,17s,18r,20s,21s,22z,25r,27s,29r,31s,34s,35s,37r,39s,41r)-17,34-dihydroxy-11-[(2e,4r)-5-hydroxy-2,4-dimethylpent-2-en-1-yl]-9,18,21,27,29,34-hexamethyl-12-methylidene-2,6,10,15,19,26,30,36,40-nonaoxanonacyclo[23.18.0.0³,²⁰.0⁵,¹⁸.0⁷,¹⁶.0⁹,¹⁴.0²⁷,⁴¹.0²⁹,³⁹.0³¹,³⁷]tritetracont-22-en-35-yl]-2-hydroxypropyl]-3-methyloxolan-2-yl]butanoic acid

C60H94O16 (1070.6541524)

(2r)-3-[(2s,5s,6s,10s)-10-[(2s)-4-[(1r,3s,6'r,8'r,8'as)-8'-hydroxy-6'-[(1s,3s)-1-hydroxy-3-[(3r,6s)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-7'-methylidene-hexahydrospiro[cyclopentane-1,2'-pyrano[3,2-b]pyran]-3-yl]but-3-en-2-yl]-5-hydroxy-8-methyl-1-oxaspiro[5.5]undec-7-en-2-yl]-2-hydroxy-2-methylpropanoic acid

(2r)-3-[(2s,5s,6s,10s)-10-[(2s)-4-[(1r,3s,6'r,8'r,8'as)-8'-hydroxy-6'-[(1s,3s)-1-hydroxy-3-[(3r,6s)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-7'-methylidene-hexahydrospiro[cyclopentane-1,2'-pyrano[3,2-b]pyran]-3-yl]but-3-en-2-yl]-5-hydroxy-8-methyl-1-oxaspiro[5.5]undec-7-en-2-yl]-2-hydroxy-2-methylpropanoic acid

C46H72O11 (800.5074362)